These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 15289492

  • 21. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer.
    Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G.
    Clin Cancer Res; 2005 Sep 15; 11(18):6625-33. PubMed ID: 16166441
    [Abstract] [Full Text] [Related]

  • 22. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
    Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR.
    Clin Cancer Res; 2006 Mar 01; 12(5):1556-63. PubMed ID: 16533781
    [Abstract] [Full Text] [Related]

  • 23. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer.
    DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, Zhu BT, Spaulding H, Goodin S, Toledano MB, Hait WN, Gallo MA.
    N Engl J Med; 1998 Sep 17; 339(12):785-91. PubMed ID: 9738085
    [Abstract] [Full Text] [Related]

  • 24. UsToo PC-SPES surveys: review of studies and update of previous survey results.
    Porterfield H.
    Mol Urol; 2000 Sep 17; 4(3):289-91;discussion 293. PubMed ID: 11062386
    [Abstract] [Full Text] [Related]

  • 25. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
    Walsh PC.
    J Urol; 2005 Jun 17; 173(6):1966. PubMed ID: 15879792
    [No Abstract] [Full Text] [Related]

  • 26. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer.
    Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW.
    Urology; 2001 Jan 17; 57(1):122-6. PubMed ID: 11164156
    [Abstract] [Full Text] [Related]

  • 27. [Chinese herbal medicine PC-SPES II induces the apoptosis of androgen-independent prostate carcinoma cell line PC-3].
    Du G, Zhang ZW, Zhang YK, Guo JM.
    Zhonghua Nan Ke Xue; 2007 Jun 17; 13(6):563-7. PubMed ID: 17615985
    [Abstract] [Full Text] [Related]

  • 28. [Clinical study of diethylstilbestrol in hormone refractory prostate cancer].
    Wang JW, Zhou LQ, Ji SQ, Song G, Li XS, He ZS.
    Zhonghua Yi Xue Za Zhi; 2011 Aug 30; 91(32):2247-9. PubMed ID: 22094088
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ.
    J Urol; 2007 Dec 30; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [Abstract] [Full Text] [Related]

  • 32. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE.
    J Natl Cancer Inst; 2007 Nov 07; 99(21):1613-22. PubMed ID: 17971530
    [Abstract] [Full Text] [Related]

  • 33. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: two case reports.
    de la Taille A, Hayek OR, Burchardt M, Burchardt T, Katz AE.
    J Altern Complement Med; 2000 Oct 07; 6(5):449-51. PubMed ID: 11059508
    [Abstract] [Full Text] [Related]

  • 34. PC-SPES withdrawal response.
    Chaudhary UB, Rashid M, Keane TE.
    Acta Oncol; 2004 Oct 07; 43(8):772-3. PubMed ID: 15764226
    [No Abstract] [Full Text] [Related]

  • 35. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.
    Choan E, Segal R, Jonker D, Malone S, Reaume N, Eapen L, Gallant V.
    Urol Oncol; 2005 Oct 07; 23(2):108-13. PubMed ID: 15869995
    [Abstract] [Full Text] [Related]

  • 36. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM.
    Cancer; 2006 Sep 01; 107(5):1093-100. PubMed ID: 16888761
    [Abstract] [Full Text] [Related]

  • 37. PC-SPES in prostate cancer.
    Small EJ.
    N Engl J Med; 1999 Feb 18; 340(7):566-7; author reply 567-8. PubMed ID: 10026050
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. PC-SPES: a brief overview.
    Cordell GA.
    Integr Cancer Ther; 2002 Sep 18; 1(3):271-86. PubMed ID: 14667285
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.